Clinical Research Directory

Inclusion Criteria: * Participants with measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1 assessed by the Investigator * Previously irradiated lesions can be considered as measurable disease only if progressive disease has been unequivocally documented at that site since radiation * Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1 * Adequate hematologic and end-organ function * Life expectancy ≥12 weeks, as determined by the Investigator * Presence of KRAS, neuroblastoma RAS viral oncogene homolog (NRAS) or Harvey rat sarcoma viral oncogene homolog (HRAS) G12V mutation in blood or tumor tissue previously determined by a local assay at any time prior to Screening * Consent to provide archival tumor tissue, if available Exclusion Criteria: * Known hypersensitivity or medical contraindication to any component of the RO7836748 formulation * Inability or unwillingness to swallow pills * Refractory nausea and vomiting, malabsorption, external biliary shunt, or significant small bowel resection that would preclude adequate study treatment absorption * Inability to comply with study and follow-up procedures * Participants with chronic diarrhea, short bowel syndrome or significant upper GI surgery including gastric resection, a history of inflammatory bowel disease (e.g., Crohn's disease or ulcerative colitis) or any active bowel inflammation (including, but not limited to, peptic ulcer disease, and diverticulitis). * Known and untreated or active central nervous system (CNS) metastases (progressing or requiring anticonvulsants or corticosteroids for symptomatic control) * Participants with any leptomeningeal disease